Justin Gover

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) shares are down after the company released its third-quarter earnings report Tuesday afternoon. Third-quarter earnings came in at a loss of 4 cents per share, which may not compare to estimates that called for an 87-cent loss. Sales came in at $90.971...

Cannabinoid-based drug maker GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) CEO Justin Gover told CNBC's Jim Cramer the company's approval to market Epidiolex across Europe is a "historic milestone" for the field of cannabinoid science. European Approval Epidiolex is the only CBD-...

GW Pharmaceuticals PLC (NASDAQ: GWPH) produces the only cannabis-derived drug approved by the Food and Drug Administration: Epidiolex, for the treatment of seizures in children.  GW is a major pharmaceutical company and shouldn't be grouped together with "sketchy" weed...

GW Pharmaceuticals (NASDAQ: GWPH) is planning to issue 1.25 million American Depositary shares in a public offering in an effort to raise some fresh cash. The company hasn't provided many details about the offering, but investors are speculating that the firm is looking to continue...